Compounds > 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
Page last updated: 2024-10-28

2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester and Pulmonary Disease, Chronic Obstructive

2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies

Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mete, A2
Bowers, K2
Chevalier, E1
Donald, DK2
Edwards, H1
Escott, KJ2
Ford, R2
Grime, K2
Millichip, I1
Teobald, B1
Russell, V2
Bull, RJ1
Coope, H1
Mather, A1
Ray, NC1

Other Studies

2 other studies available for 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester and Pulmonary Disease, Chronic Obstructive

ArticleYear
The discovery of AZD9164, a novel muscarinic M3 antagonist.
    Bioorganic & medicinal chemistry letters, 2011, Dec-15, Volume: 21, Issue:24

    Topics: Blood Proteins; Drug Evaluation, Preclinical; Humans; Muscarinic Antagonists; Piperidines; Protein B

2011
The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD.
    Bioorganic & medicinal chemistry letters, 2013, Dec-01, Volume: 23, Issue:23

    Topics: Administration, Inhalation; Animals; Bronchoconstriction; Cycloheptanes; Disease Models, Animal; Gui

2013